198 related articles for article (PubMed ID: 30771580)
1. Trial of intrathecal rituximab in progressive multiple sclerosis patients with evidence of leptomeningeal contrast enhancement.
Bhargava P; Wicken C; Smith MD; Strowd RE; Cortese I; Reich DS; Calabresi PA; Mowry EM
Mult Scler Relat Disord; 2019 May; 30():136-140. PubMed ID: 30771580
[TBL] [Abstract][Full Text] [Related]
2. Association of MRI leptomeningeal enhancement with disability worsening in progressive multiple sclerosis: A clinical and post-mortem study.
Vercellino M; Costantini G; Cogoni M; Lequio L; Sciortino P; De Negri F; Marasciulo S; Valentini C; Bosa C; Garelli P; Rolando A; Calvo A; Morana G; Cavalla P
Mult Scler; 2023 Nov; 29(13):1526-1539. PubMed ID: 37740714
[TBL] [Abstract][Full Text] [Related]
3. The effects of intrathecal rituximab on biomarkers in multiple sclerosis.
Topping J; Dobson R; Lapin S; Maslyanskiy A; Kropshofer H; Leppert D; Giovannoni G; Evdoshenko E
Mult Scler Relat Disord; 2016 Mar; 6():49-53. PubMed ID: 27063622
[TBL] [Abstract][Full Text] [Related]
4. Highly Sensitive 3-Tesla Real Inversion Recovery MRI Detects Leptomeningeal Contrast Enhancement in Chronic Active Multiple Sclerosis.
Okar SV; Dieckhaus H; Beck ES; Gaitán MI; Norato G; Pham DL; Absinta M; Cortese IC; Fletcher A; Jacobson S; Nair G; Reich DS
Invest Radiol; 2024 Mar; 59(3):243-251. PubMed ID: 37493285
[TBL] [Abstract][Full Text] [Related]
5. 7T MRI cerebral leptomeningeal enhancement is common in relapsing-remitting multiple sclerosis and is associated with cortical and thalamic lesions.
Zurawski J; Tauhid S; Chu R; Khalid F; Healy BC; Weiner HL; Bakshi R
Mult Scler; 2020 Feb; 26(2):177-187. PubMed ID: 31714181
[TBL] [Abstract][Full Text] [Related]
6. Leptomeningeal Enhancement on 3D-FLAIR MRI in Multiple Sclerosis: Systematic Observations in Clinical Practice.
Titelbaum DS; Engisch R; Schwartz ED; Napoli SQ; Sloane JA; Samaan S; Katz JD; Lathi ES
J Neuroimaging; 2020 Nov; 30(6):917-929. PubMed ID: 32830899
[TBL] [Abstract][Full Text] [Related]
7. Focal cortical atrophy following transient meningeal enhancement in a progressive multiple sclerosis.
Bonnan M; Money P; Desblache P; Marasescu R; Puvilland LM; Demasles S; Dahan C; Krim E; Tucholka A; Doyle S; Barroso B
Neurol Sci; 2021 May; 42(5):1959-1961. PubMed ID: 32995987
[TBL] [Abstract][Full Text] [Related]
8. No association between cortical lesions and leptomeningeal enhancement on 7-Tesla MRI in multiple sclerosis.
Ighani M; Jonas S; Izbudak I; Choi S; Lema-Dopico A; Hua J; O'Connor EE; Harrison DM
Mult Scler; 2020 Feb; 26(2):165-176. PubMed ID: 31573837
[TBL] [Abstract][Full Text] [Related]
9. Natalizumab in progressive MS: results of an open-label, phase 2A, proof-of-concept trial.
Romme Christensen J; Ratzer R; Börnsen L; Lyksborg M; Garde E; Dyrby TB; Siebner HR; Sorensen PS; Sellebjerg F
Neurology; 2014 Apr; 82(17):1499-507. PubMed ID: 24682973
[TBL] [Abstract][Full Text] [Related]
10. Intrathecal treatment trial of rituximab in progressive MS: An open-label phase 1b study.
Bergman J; Burman J; Gilthorpe JD; Zetterberg H; Jiltsova E; Bergenheim T; Svenningsson A
Neurology; 2018 Nov; 91(20):e1893-e1901. PubMed ID: 30305449
[TBL] [Abstract][Full Text] [Related]
11. Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy.
Salzer J; Svenningsson R; Alping P; Novakova L; Björck A; Fink K; Islam-Jakobsson P; Malmeström C; Axelsson M; Vågberg M; Sundström P; Lycke J; Piehl F; Svenningsson A
Neurology; 2016 Nov; 87(20):2074-2081. PubMed ID: 27760868
[TBL] [Abstract][Full Text] [Related]
12. Leptomeningeal gadolinium enhancement across the spectrum of chronic neuroinflammatory diseases.
Absinta M; Cortese IC; Vuolo L; Nair G; de Alwis MP; Ohayon J; Meani A; Martinelli V; Scotti R; Falini A; Smith BR; Nath A; Jacobson S; Filippi M; Reich DS
Neurology; 2017 Apr; 88(15):1439-1444. PubMed ID: 28283598
[TBL] [Abstract][Full Text] [Related]
13. A pilot trial of ocrelizumab for modulation of meningeal enhancement in multiple sclerosis.
Dahal S; Allette YM; Naunton K; Harrison DM
Mult Scler Relat Disord; 2024 Jan; 81():105344. PubMed ID: 38035495
[TBL] [Abstract][Full Text] [Related]
14. Meningeal contrast enhancement in multiple sclerosis: Assessment of field strength, acquisition delay, and clinical relevance.
Harrison DM; Allette YM; Zeng Y; Cohen A; Dahal S; Choi S; Zhuo J; Hua J
PLoS One; 2024; 19(5):e0300298. PubMed ID: 38809920
[TBL] [Abstract][Full Text] [Related]
15. Location matters: highly divergent protein levels in samples from different CNS compartments in a clinical trial of rituximab for progressive MS.
Bergman J; Svenningsson A; Liv P; Bergenheim T; Burman J
Fluids Barriers CNS; 2020 Jul; 17(1):49. PubMed ID: 32727487
[TBL] [Abstract][Full Text] [Related]
16. Rituximab for secondary progressive multiple sclerosis: a case series.
Rommer PS; Patejdl R; Winkelmann A; Benecke R; Zettl UK
CNS Drugs; 2011 Jul; 25(7):607-13. PubMed ID: 21699272
[TBL] [Abstract][Full Text] [Related]
17. Leptomeningeal enhancement under different MS immunotherapies: A monocentric retrospective cohort study of 214 patients.
Friedli C; Wagner F; Hammer HN; Kamber N; Wiest R; Diem L; Chan A; Salmen A; Hoepner R
Mult Scler; 2023 Jan; 29(1):63-73. PubMed ID: 36113094
[TBL] [Abstract][Full Text] [Related]
18. Leptomeningeal enhancement in multiple sclerosis and other neurological diseases: A systematic review and Meta-Analysis.
Ineichen BV; Tsagkas C; Absinta M; Reich DS
Neuroimage Clin; 2022; 33():102939. PubMed ID: 35026625
[TBL] [Abstract][Full Text] [Related]
19. Peripheral B cell depletion and central proinflammatory cytokine reduction following repeated intrathecal administration of rituximab in progressive Multiple Sclerosis.
Studer V; Rossi S; Motta C; Buttari F; Centonze D
J Neuroimmunol; 2014 Nov; 276(1-2):229-31. PubMed ID: 25175066
[TBL] [Abstract][Full Text] [Related]
20. Leptomeningeal Contrast Enhancement Is Related to Focal Cortical Thinning in Relapsing-Remitting Multiple Sclerosis: A Cross-Sectional MRI Study.
Bergsland N; Ramasamy D; Tavazzi E; Hojnacki D; Weinstock-Guttman B; Zivadinov R
AJNR Am J Neuroradiol; 2019 Apr; 40(4):620-625. PubMed ID: 30872420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
